MNKD Mannkind Corp

Price (delayed)

$4.565

Market cap

$1.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.36

Enterprise value

$1.36B

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its ...

Highlights
Mannkind's gross profit has increased by 39% YoY and by 9% from the previous quarter
The revenue has grown by 20% YoY and by 12% from the previous quarter
Mannkind's quick ratio has surged by 185% YoY but it has decreased by 27% QoQ
The company's debt has surged by 131% YoY but it fell by 14% QoQ
Mannkind's net income has plunged by 95% YoY and by 42% from the previous quarter
Mannkind's EPS has plunged by 71% YoY and by 33% from the previous quarter

Key stats

What are the main financial stats of MNKD
Market
Shares outstanding
249.66M
Market cap
$1.14B
Enterprise value
$1.36B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
15.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.29
Earnings
Revenue
$74.51M
EBIT
-$71.92M
EBITDA
-$67.93M
Free cash flow
-$49.93M
Per share
EPS
-$0.36
Free cash flow per share
-$0.2
Book value per share
-$0.74
Revenue per share
$0.3
TBVPS
$1.01
Balance sheet
Total assets
$252.79M
Total liabilities
$436.34M
Debt
$285.69M
Equity
-$183.55M
Working capital
$119.47M
Liquidity
Debt to equity
-1.56
Current ratio
2.98
Quick ratio
2.79
Net debt/EBITDA
-3.29
Margins
EBITDA margin
-91.2%
Gross margin
61.1%
Net margin
-115.6%
Operating margin
-59.5%
Efficiency
Return on assets
-44.4%
Return on equity
N/A
Return on invested capital
-32.1%
Return on capital employed
-37.4%
Return on sales
-96.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNKD stock price

How has the Mannkind stock price performed over time
Intraday
0.11%
1 week
-2.87%
1 month
10%
1 year
136.53%
YTD
45.85%
QTD
-16.24%

Financial performance

How have Mannkind's revenue and profit performed over time
Revenue
$74.51M
Gross profit
$45.52M
Operating income
-$44.34M
Net income
-$86.11M
Gross margin
61.1%
Net margin
-115.6%
Mannkind's net income has plunged by 95% YoY and by 42% from the previous quarter
The company's net margin has shrunk by 62% YoY and by 26% QoQ
Mannkind's gross profit has increased by 39% YoY and by 9% from the previous quarter
MNKD's operating income is down by 22% YoY and by 8% QoQ

Growth

What is Mannkind's growth rate over time

Valuation

What is Mannkind stock price valuation
P/E
N/A
P/B
N/A
P/S
15.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.29
Mannkind's EPS has plunged by 71% YoY and by 33% from the previous quarter
The equity has declined by 6% since the previous quarter and by 2.1% year-on-year
The P/S is 68% higher than the 5-year quarterly average of 9.1 and 21% higher than the last 4 quarters average of 12.6
The revenue has grown by 20% YoY and by 12% from the previous quarter

Efficiency

How efficient is Mannkind business performance
Mannkind's ROS has plunged by 87% YoY and by 35% from the previous quarter
The ROA is down by 14% QoQ but it is up by 7% YoY
The company's return on invested capital fell by 8% YoY but it rose by 2.7% QoQ

Dividends

What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNKD.

Financial health

How did Mannkind financials performed over time
The company's total assets is 42% lower than its total liabilities
Mannkind's quick ratio has surged by 185% YoY but it has decreased by 27% QoQ
The company's current ratio has surged by 179% YoY but it fell by 24% QoQ
The company's debt has surged by 131% YoY but it fell by 14% QoQ
The debt to equity has dropped by 126% year-on-year but it is up by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.